Applied Therapeutics (APLT) CCO exits stake after $0.088-per-share cash and CVR deal

Rhea-AI Filing Summary

Applied Therapeutics Chief Commercial Officer Hooks Corwin Dale reported merger-related equity transactions and a prior grant of restricted stock units (RSUs). On December 19, 2025, he received 312,500 RSUs under the 2019 Equity Incentive Plan, vesting upon a Change in Control or June 19, 2026, if he remained in service.

A merger with Cycle Group Holdings Limited and AT2B, Inc. became effective on January 28, 2026. At that time, each share of Applied Therapeutics common stock and each RSU was cancelled and converted into the right to receive $0.088 per share in cash plus one non-tradeable contingent value right.

On February 3, 2026, Dale reported the disposition of 862,500 shares of common stock and a further 5,753 shares, all exchanged for the merger consideration, leaving him with no directly held shares. The filing also notes a correction of earlier administrative understatement of his total holdings.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Hooks Corwin Dale

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Disposition	Common Stock	862,500	$0.00	--
U	Common Stock	5,753	$0.00	--
Grant/Award	Common Stock	312,500	$0.00	--

Holdings After Transaction: Common Stock — 5,753 shares (Direct)

Footnotes (1)

1. Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date. The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the understatement of the total holdings. Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hooks Corwin Dale

(Last) (First) (Middle)

C/O APPLIED THERAPEUTICS, INC.

545 FIFTH AVENUE, SUITE 1400

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Applied Therapeutics, Inc. [ APLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/19/2025		A(1)		312,500	A	$0	868,253(2)	D
Common Stock	02/03/2026		D(3)(4)		862,500	D	(3)(4)	5,753	D
Common Stock	02/03/2026		U(3)(5)		5,753	D	(5)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.

2. The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the understatement of the total holdings.

3. Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").

4. Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.

5. Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.

	/s/ Leslie D. Funtleyder, as attorney-in-fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did APLT Chief Commercial Officer Hooks Corwin Dale report?

Hooks Corwin Dale reported receiving 312,500 restricted stock units and later disposing of 862,500 Applied Therapeutics common shares plus 5,753 additional shares. These shares and units were cancelled and converted into the agreed merger consideration when the company completed its merger with Cycle Group Holdings Limited.

What were the terms of the Applied Therapeutics (APLT) merger consideration?

Each Applied Therapeutics common share was converted into the right to receive $0.088 in cash plus one non-tradeable contingent value right. This package, defined as the merger consideration, was provided under the Agreement and Plan of Merger once the merger became effective on January 28, 2026.

How many RSUs did the APLT Chief Commercial Officer receive and when do they vest?

Hooks Corwin Dale received 312,500 compensatory RSUs on December 19, 2025 under Applied Therapeutics’ 2019 Equity Incentive Plan. Each RSU represents one share and was scheduled to vest in full upon a Change in Control or on June 19, 2026, subject to continued service.

What happened to APLT RSUs and common stock in the merger?

At the effective time of the merger, each outstanding Applied Therapeutics common share and each RSU, whether vested or unvested, was cancelled. In exchange, holders received the merger consideration of $0.088 per share in cash plus one non-tradeable contingent value right, as specified in the merger agreement.

Did the APLT Chief Commercial Officer hold any shares after the reported transactions?

After the February 3, 2026 transactions, the Form 4 shows Hooks Corwin Dale with zero directly held Applied Therapeutics shares. His previously held common stock and RSUs were cancelled and exchanged for the merger consideration of cash and contingent value rights under the completed merger.

Why were the APLT Chief Commercial Officer’s total holdings adjusted in this Form 4?

The filing explains that total holdings were adjusted to correct an administrative error in prior Form 4s. Those earlier filings had understated the true number of securities beneficially owned, and this correction aligns the reported holdings with the accurate historical amounts before the merger transactions.